These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33811118)

  • 1. Emerging Trends in Cancer Drug Discovery-From Drugging the "Undruggable" to Overcoming Resistance.
    Rudolph J; Settleman J; Malek S
    Cancer Discov; 2021 Apr; 11(4):815-821. PubMed ID: 33811118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers.
    Wolpaw AJ; Bayliss R; Büchel G; Dang CV; Eilers M; Gustafson WC; Hansen GH; Jura N; Knapp S; Lemmon MA; Levens D; Maris JM; Marmorstein R; Metallo SJ; Park JR; Penn LZ; Rape M; Roussel MF; Shokat KM; Tansey WP; Verba KA; Vos SM; Weiss WA; Wolf E; Mossé YP
    Cancer Res; 2021 Apr; 81(7):1627-1632. PubMed ID: 33509943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugging the 'undruggable' cancer targets.
    Dang CV; Reddy EP; Shokat KM; Soucek L
    Nat Rev Cancer; 2017 Aug; 17(8):502-508. PubMed ID: 28643779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerating safe drug development: an ideal approach to approval.
    Grever MR
    Hematology Am Soc Hematol Educ Program; 2013; 2013():24-9. PubMed ID: 24319158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugging the 'undruggable'. Therapeutic targeting of protein-DNA interactions with the use of computer-aided drug discovery methods.
    Radaeva M; Ton AT; Hsing M; Ban F; Cherkasov A
    Drug Discov Today; 2021 Nov; 26(11):2660-2679. PubMed ID: 34332092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming cancer resistance.
    Cook KL; Clarke R
    Future Med Chem; 2015 Aug; 7(12):1471. PubMed ID: 26334204
    [No Abstract]   [Full Text] [Related]  

  • 7. (Part I) Recent trends in anti-cancer drug discovery.
    Sarkar FH
    Mini Rev Med Chem; 2010 May; 10(5):357-8. PubMed ID: 20482491
    [No Abstract]   [Full Text] [Related]  

  • 8. Challenges in the Discovery of Novel Therapeutic Agents in Cancer.
    Nagaraju GP; Kamal MA
    Curr Drug Metab; 2019; 20(12):931-932. PubMed ID: 31989914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules.
    Yang W; Gadgil P; Krishnamurthy VR; Landis M; Mallick P; Patel D; Patel PJ; Reid DL; Sanchez-Felix M
    AAPS J; 2020 Jan; 22(2):21. PubMed ID: 31900602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.
    Mosca L; Ilari A; Fazi F; Assaraf YG; Colotti G
    Drug Resist Updat; 2021 Jan; 54():100742. PubMed ID: 33429249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reimagining Druggability Using Chemoproteomic Platforms.
    Spradlin JN; Zhang E; Nomura DK
    Acc Chem Res; 2021 Apr; 54(7):1801-1813. PubMed ID: 33733731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic lethality as an engine for cancer drug target discovery.
    Huang A; Garraway LA; Ashworth A; Weber B
    Nat Rev Drug Discov; 2020 Jan; 19(1):23-38. PubMed ID: 31712683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1.
    Gillet JP; Gottesman MM
    Drug Resist Updat; 2012; 15(1-2):2-4. PubMed ID: 22465109
    [No Abstract]   [Full Text] [Related]  

  • 14. Challenges in the Discovery of Novel Therapeutic Agents in Cancer.
    Nagaraju GP; Kamal MA
    Curr Drug Metab; 2019; 20(13):1004-1005. PubMed ID: 32072882
    [No Abstract]   [Full Text] [Related]  

  • 15. Drugging K-Ras
    Ni D; Li X; He X; Zhang H; Zhang J; Lu S
    Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Special Issue: Natural Products: Anticancer and Beyond.
    Cui Q; Yang DH; Chen ZS
    Molecules; 2018 May; 23(6):. PubMed ID: 29882875
    [No Abstract]   [Full Text] [Related]  

  • 17. Network systems biology for targeted cancer therapies.
    Zhou TT
    Chin J Cancer; 2012 Mar; 31(3):134-41. PubMed ID: 22176777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanobiotechnological Approaches to Overcome Drug Resistance in Breast Cancer.
    Ranji P; Heydari Z; Alizadeh AM
    Curr Cancer Drug Targets; 2015; 15(7):544-62. PubMed ID: 26143946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members.
    Verdine GL; Walensky LD
    Clin Cancer Res; 2007 Dec; 13(24):7264-70. PubMed ID: 18094406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugging the p53 pathway: understanding the route to clinical efficacy.
    Khoo KH; Verma CS; Lane DP
    Nat Rev Drug Discov; 2014 Mar; 13(3):217-36. PubMed ID: 24577402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.